Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

70.45USD
22 Jun 2018
Change (% chg)

$3.10 (+4.60%)
Prev Close
$67.35
Open
$67.45
Day's High
$71.30
Day's Low
$65.70
Volume
448,383
Avg. Vol
116,988
52-wk High
$71.30
52-wk Low
$47.05

Chart for

About

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02%... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $2,602.82
Shares Outstanding(Mil.): 39.50
Dividend: --
Yield (%): --

Financials

  AERI.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -4.37 -- --
ROI: -55.39 -5.33 13.09
ROE: -99.89 -6.88 15.10

BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm

* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%

May 15 2018

BRIEF-Aerie Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.83

* AERIE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 08 2018

BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%

* AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%

Apr 30 2018

BRIEF-Aerie Pharmaceuticals CEO Vicente Anido's 2017 Total Compensation Was $10.06 Million

* AERIE PHARMACEUTICALS INC SAYS CEO VICENTE ANIDO'S 2017 TOTAL COMPENSATION WAS $10.06 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2Kn2hS6) Further company coverage:

Apr 27 2018

BRIEF-Aerie Pharmaceuticals Reports Q4 Adjusted Loss Per Share $1.38

* AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AND 2018 GUIDANCE

Feb 28 2018

BRIEF-Aerie Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Jan 24 2018

BRIEF-Aerie Pharmaceuticals Commences Public Offering Of $75 Million Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

Jan 23 2018

BRIEF-Aerie Pharmaceuticals Appoints Julia Williams As Director Of Medical Affairs

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF JULIA WILLIAMS AS DIRECTOR OF MEDICAL AFFAIRS Source text for Eikon: Further company coverage:

Jan 02 2018

Earnings vs. Estimates